8-K: CytoSorbents Reports Strong Q4 and Full Year 2024 Financial Results, Anticipates DrugSorb-ATR Regulatory Decisions in 2025

CytoSorbents announces a 25% increase in Q4 product revenue and expects regulatory decisions for DrugSorb-ATR in 2025.

Summary

• CytoSorbents Corporation reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Product revenue for Q4 2024 was $9.2 million, a 25% increase compared to $7.3 million in Q4 2023.
• Grant income was $1.0 million in Q4 2024, compared to $1.3 million in Q4 2023; the company has changed its accounting method for grant income.
• Product gross margin was 71% in Q4 2024, compared to 68% in Q4 2023.
• Operating loss improved by 61% to $3.7 million in Q4 2024, compared to $9.6 million in Q4 2023.
• Net loss was $7.6 million, or $0.14 per share, compared to a net loss of $6.1 million, or $0.13 per share in Q4 2023.
• Adjusted EBITDA loss improved by 70% to $2.4 million compared to a loss of $8.1 million in Q4 2023.
• Full year 2024 product revenue was $35.6 million, a 15% increase compared to $31.1 million in 2023.
• Operating loss for 2024 improved by 47% to $16.8 million compared to $32 million in 2023.
• Net loss for 2024 was $20.7 million, or $0.38 per share, compared to a net loss of $29.2 million, or $0.65 per share in 2023.
• The company expects regulatory decisions for DrugSorb-ATR from Health Canada and the US FDA in 2025.
• A successful rights offering and exercise of Series A Right Warrants strengthened the balance sheet.
• The company anticipates a short-term disruption in Germany sales in Q1 2025 due to sales team restructuring.

Sentiment

Score: 7

Explanation: The report is generally positive, highlighting strong revenue growth, improved margins, and progress towards regulatory approvals. However, the company acknowledges challenges in Germany and ongoing net losses, tempering the overall sentiment.

Positives

• Product revenue increased by 25% in Q4 2024 compared to Q4 2023.
• Product gross margin was a healthy 71% in Q4 2024.
• Operating loss improved significantly in both Q4 and full year 2024.
• The company successfully executed a Shareholder Rights Offering, raising $7.3 million.
• The company expects regulatory decisions for DrugSorb-ATR from Health Canada and the US FDA in 2025.
• The company is seeing strong growth in direct sales outside of Germany and in Distributor/Partner sales.

Negatives

• Net loss was $7.6 million in Q4 2024, although adjusted net loss improved.
• The company anticipates a short-term disruption in Germany sales in Q1 2025 due to sales team restructuring.
• Germany sales were flat for the second year in a row.

Risks

• The company's restructuring of its direct sales team in Germany may lead to a short-term disruption in sales.
• Regulatory approval for DrugSorb-ATR is not guaranteed.
• The company's future performance depends on its ability to successfully commercialize its products.
• The company's success depends on the adoption of CytoSorb by medical professionals.

Future Outlook

The company anticipates opportunities to expand its business internationally and in the United States and Canada, expecting regulatory decisions for DrugSorb-ATR in 2025 and aiming to restore sales growth in Germany.

Management Comments

• Dr. Phillip Chan, CEO, stated that the company delivered a strong fourth quarter, executing on key initiatives that drove solid performance, advanced regulatory milestones, and fortified the financial position.
• Dr. Chan believes the company has a clear and compelling value proposition.
• Dr. Chan stated that the company is well-positioned to take advantage of new opportunities this year.

Industry Context

CytoSorbents operates in the blood purification market, focusing on critical care and cardiac surgery. The company's DrugSorb-ATR targets the reduction of perioperative bleeding in patients on blood thinners, addressing a significant unmet need in the market.

Comparison to Industry Standards

• Comparable companies in the blood purification and medical device space include Baxter International, Fresenius Medical Care, and Medtronic.
• CytoSorbents' 71% gross margin is competitive with other medical device companies.
• The company's focus on innovation and regulatory approvals aligns with industry trends.
• The estimated $1 billion addressable market for DrugSorb-ATR reflects the significant potential in the antithrombotic removal market.

Stakeholder Impact

• Shareholders benefit from the company's revenue growth and improved financial performance.
• Patients may benefit from the potential approval and launch of DrugSorb-ATR.
• Employees may be affected by the restructuring of the sales team in Germany.

Next Steps

• The company is preparing for the potential launch of DrugSorb-ATR.
• The company is restructuring its sales team in Germany to improve sales growth.
• The company will present new data at major cardiovascular conferences.

Key Dates

Keywords

CytoSorbents, DrugSorb-ATR, Financial Results, Blood Purification, Regulatory Approval, Product Revenue, Gross Margin, Operating Loss, Net Loss, EBITDA, Rights Offering, Germany Sales, Cardiac Surgery, Critical Care